We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTX
126
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.13M 0.13%
567,552
– –
PANA.U
127
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$4.83M 0.12%
+402,088
New +$4.63M
PHAS
128
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$4.61M 0.12%
1,313,174
+169,249
+15% +$682K
ANAB icon
129
AnaptysBio
ANAB
$1.68B
$4.56M 0.12%
309,113
+2,400
+0.8% +$43.3K
CYTK icon
130
Cytokinetics
CYTK
$10.7B
$4.47M 0.11%
206,495
+129,078
+167% +$3.02M
OBSV
131
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.56M 0.09%
1,434,652
+11,100
+0.8% +$31.7K
PSTX
132
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.26M 0.08%
+367,499
New +$4.18M
CO
133
DELISTED
Global Cord Blood Corporation
CO
$3.2M 0.08%
904,800
-20,200
-2% -$70K
PASG icon
134
Passage Bio
PASG
$14.9M
$2.7M 0.07%
10,302
+130
+1% +$44.7K
VRTX icon
135
Vertex Pharmaceuticals
VRTX
$135B
$2.45M 0.06%
9,000
-116,000
-93% -$32M
IGMS
136
DELISTED
IGM Biosciences
IGMS
$1.46M 0.04%
19,762
-75,516
-79% -$4.47M
FPRX
137
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.28M 0.03%
271,585
-135,144
-33% -$686K
NBRV
138
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$569K 0.01%
4,271
– –
BMY.RT
139
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$417K 0.01%
185,150
– –
ALLO icon
140
Allogene Therapeutics
ALLO
$728M
– –
-440,468
Closed -$18.9M
AMGN icon
141
Amgen
AMGN
$224B
– –
-126,000
Closed -$29.7M
BNR
142
Burning Rock Biotech
BNR
$110M
– –
-20,000
Closed -$5.4M
CI icon
143
Cigna
CI
$71.9B
– –
-161,000
Closed -$30.2M
JNJ icon
144
Johnson & Johnson
JNJ
$627B
– –
-105,000
Closed -$14.8M
RPTX
145
DELISTED
Repare Therapeutics
RPTX
– –
-274,815
Closed -$8.53M
STAA icon
146
STAAR Surgical
STAA
$1.25B
– –
-130,000
Closed -$8M
QTTB icon
147
Q32 Bio
QTTB
$458M
– –
-19,535
Closed -$5.34M
NARI
148
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-80,000
Closed -$3.88M
DCPH
149
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-209,829
Closed -$12.5M
BLU
150
DELISTED
BELLUS Health Inc.
BLU
– –
-696,115
Closed -$7.16M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.